Complement protein regulation and inflammation alterations in transthyretin amyloidosis progression have been previously reported [48,49], and our observation adds to the intriguing possibility that markers of inflammation could be used to inform decisions about when to start treating patients with tafamidis or another disease-modifying ATTR therapy. The gene discussed is TTR; the disease is amyloidosis.